Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Kither Biotech.

    Client Virtual Booth

    KITHER BIOTECH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Kither Biotech
    Italy Flag
    Country
    Country
    Italy
    Address
    Address
    Via Nizza 52, Torino
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://kitherbiotech.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/kither-biotech
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Kither Biotech Announces Publication of New Data in Science Translational Medicine

    Details:

    KIT2014, a novel, cell-permeable peptide that works to modulate cAMP levels inside cells, demonstrated a triple mechanism of action in reversing disease pathogenesis: enhancing functionality of CFTR channels and reducing bronchoconstriction and inflammation.


    Lead Product(s): KIT2014

    Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KIT2014

    Highest Development Status: PreclinicalProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 31, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer

    Details:

    Proceeds will be used to fund the clinical development of Kither’s lead product KIT2014, a novel cell- permeable peptide for the treatment of cystic fibrosis (CF) that works to modulate cyclic adenosine monophosphate (cAMP) levels inside cells.


    Lead Product(s): KIT2014

    Therapeutic Area: Genetic Disease Product Name: KIT2014

    Highest Development Status: PreclinicalProduct Type: Peptide

    Partner/Sponsor/Collaborator: Claris Ventures

    Deal Size: $18.5 million Upfront Cash: Undisclosed

    Deal Type: Series B Financing March 16, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search